Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Haohai Biological Technology Co., Ltd. (688366.SS)
Shanghai, CN
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.08% | -0.66% | -13.09% | -25.05% | -30.38% | -21.50% | -33.92% | -44.98% | -76.23% | -63.09% | -63.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-8.2% Q1'26: -7.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-40.0% Q1'26: -15.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+10.1% Q1'26: -14.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+9.7% ★ Q1'26: +12.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+6.9% ★ Q1'26: +6.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.3% ★ Q1'26: -2.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.96× ★ Q1'26: 1.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
663.92M
est: 693.82M (-4.3%)
|
851.16M
est: 846.00M (+0.6%)
|
1.34B
est: 1.34B (+0.1%)
|
1.55B
est: 1.62B (-4.5%)
|
1.60B
est: 1.82B (-12.3%)
|
1.32B
est: 1.31B (+0.8%)
|
1.75B
est: 1.72B (+1.6%)
|
2.10B
est: 2.14B (-1.8%)
|
2.63B
est: 2.61B (+0.9%)
|
2.68B
est: 2.91B (-8.0%)
|
2.46B
est: 2.76B (-10.9%)
|
2.61B
2.61B – 2.61B
-5.4% YoY
|
2.76B
2.76B – 2.76B
+5.6% YoY
|
2.88B
2.88B – 2.88B
+4.2% YoY
|
| EBITDA |
353.93M
est: 128.76M (+174.9%)
|
401.14M
est: 157.00M (+155.5%)
|
530.83M
est: 249.21M (+113.0%)
|
609.53M
est: 300.27M (+103.0%)
|
535.77M
est: 337.51M (+58.7%)
|
375.31M
est: 243.78M (+54.0%)
|
522.74M
est: 319.78M (+63.5%)
|
421.95M
est: 397.49M (+6.2%)
|
689.02M
est: 484.77M (+42.1%)
|
661.24M
est: 685.37M (-3.5%)
|
416.56M
est: 649.85M (-35.9%)
|
614.63M
614.63M – 614.63M
-5.4% YoY
|
649.19M
649.19M – 649.19M
+5.6% YoY
|
676.23M
676.23M – 676.23M
+4.2% YoY
|
| EBIT |
320.65M
est: 76.08M (+321.5%)
|
366.10M
est: 92.77M (+294.6%)
|
463.83M
est: 147.25M (+215.0%)
|
528.37M
est: 177.42M (+197.8%)
|
438.89M
est: 199.42M (+120.1%)
|
261.93M
est: 144.04M (+81.8%)
|
387.61M
est: 188.95M (+105.1%)
|
243.33M
est: 234.86M (+3.6%)
|
515.56M
est: 286.44M (+80.0%)
|
484.21M
est: 472.29M (+2.5%)
|
239.53M
est: 447.81M (-46.5%)
|
423.54M
423.54M – 423.54M
-5.4% YoY
|
447.36M
447.36M – 447.36M
+5.6% YoY
|
465.99M
465.99M – 465.99M
+4.2% YoY
|
| Net Income |
273.47M
est: 283.45M (-3.5%)
|
305.05M
est: 314.23M (-2.9%)
|
372.42M
est: 389.49M (-4.4%)
|
414.54M
est: 468.93M (-11.6%)
|
370.78M
est: 509.74M (-27.3%)
|
230.07M
est: 211.46M (+8.8%)
|
352.23M
est: 380.82M (-7.5%)
|
180.47M
est: 245.45M (-26.5%)
|
416.12M
est: 418.59M (-0.6%)
|
420.45M
est: 448.56M (-6.3%)
|
251.01M
est: 443.91M (-43.5%)
|
385.81M
385.81M – 385.81M
-13.1% YoY
|
421.83M
421.83M – 421.83M
+9.3% YoY
|
450.88M
450.88M – 450.88M
+6.9% YoY
|
| SGA |
300.98M
est: 350.81M (-14.2%)
|
377.95M
est: 427.76M (-11.6%)
|
608.84M
est: 679.00M (-10.3%)
|
737.49M
est: 818.10M (-9.9%)
|
809.54M
est: 919.56M (-12.0%)
|
767.35M
est: 664.19M (+15.5%)
|
894.69M
est: 871.25M (+2.7%)
|
1.08B
est: 1.08B (-0.2%)
|
1.23B
est: 1.32B (-6.7%)
|
1.22B
est: 1.14B (+7.7%)
|
—
est: 1.08B (-100.0%)
|
1.02B
1.02B – 1.02B
-5.4% YoY
|
1.08B
1.08B – 1.08B
+5.6% YoY
|
1.12B
1.12B – 1.12B
+4.2% YoY
|
| EPS |
0.95
est: 1.22 (-21.9%)
|
0.97
est: 1.35 (-28.0%)
|
1.19
est: 1.67 (-28.8%)
|
1.32
est: 2.01 (-34.4%)
|
1.16
est: 2.19 (-47.0%)
|
0.66
est: 0.91 (-27.2%)
|
1.02
est: 1.63 (-37.6%)
|
0.53
est: 1.05 (-49.7%)
|
1.75
est: 1.80 (-2.5%)
|
1.80
est: 1.93 (-6.7%)
|
1.08
est: 1.91 (-43.5%)
|
1.66
1.66 – 1.66
-13.1% YoY
|
1.82
1.82 – 1.82
+9.3% YoY
|
1.94
1.94 – 1.94
+6.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 15.2K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 34.3K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.69M | 0.06% |
| 4 | Vanguard ESG International Stock ETF VSGX | 0.00% | 9.9K | 0.10% |
| 5 | Vanguard Total International Stock ETF VXUS | 0.00% | 932.4K | 0.05% |
| 6 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.7K | 0.22% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 8.2K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 4.4K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 1.9K | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 224.43 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yongtai Hou | Executive Chairman | 3M | — |
| Jianying Wu | GM & Executive Director | 3M | — |
| Minjie Tang | Chief Financial Officer & Executive Director | 2M | male |
| Yiyi Chen | Executive Director | 2M | female |
| Min Tian | Joint Company Secretary | — | female |
| Ying Tung Lai | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688366.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
